Latest News

Cutaneous lupus: Switching antimalarials can delay immunosuppressive therapy


 

EXPERT ANALYSIS FROM ICCLE 2018


In patients with highly active skin disease at baseline, Dr. Fernandez said he will sometimes start hydroxychloroquine higher than 400 mg initially but will bring patients back down to 400 mg after a few months.

Dr. Fernandez had no relevant disclosures.

Pages

Recommended Reading

VIDEO: Characteristic flora define intestinal microbiome in scleroderma
MDedge Rheumatology
VIDEO: Calming microglia might control fibromyalgia
MDedge Rheumatology
Newer IgG4 testing proving effective in assessing patients
MDedge Rheumatology
New agents may bring hope for SLE patients
MDedge Rheumatology
Caution crucial for stem cell transplant in scleroderma, despite potential interest
MDedge Rheumatology
Don’t trust interface dermatitis to diagnose dermatomyositis
MDedge Rheumatology
Median time to progression from discoid to systemic lupus may be less than a year
MDedge Rheumatology
Timely dermatomyositis diagnosis, treatment remain elusive
MDedge Rheumatology
Hydroxychloroquine throws off Quantiferon-TB Gold results, study finds
MDedge Rheumatology
Idiopathic pulmonary fibrosis a ‘robust diagnosis’
MDedge Rheumatology